TRVI News and Press, Trevi Therapeutics Inc. From 06/27/20

The following healthcare companies have filed for mixed shelf offerings: More news on: Veru Inc., Cancer Genetics, Inc., Trevi Therapeutics, Inc., Healthcare stocks news, , Read more ...

NEW HAVEN, Conn., June 17, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that management will...

NEW HAVEN, Conn., May 29, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that, due to the ...

Sample Size Re-Estimation Analysis for PRISM Trial Expected in Mid-2020 New Patient Screening Re-Starting at PRISM Sites in the US and Europe Cash Position of $52.6 Million Expected to Fund Operations into the Fourth Quarter of 2021 NEW HAVEN, Conn., May 07, 2020 (GLOBE NEWSWIR...

NEW HAVEN, Conn., April 08, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that management wil...

Gainers: Trevi Therapeutics (NASDAQ: TRVI ) +109% . More news on: Trevi Therapeutics, Inc., SG Blocks, Inc., Greenland Technologies Holding Corporation, Stocks on the move, , Read more ...

Ultra-thinly traded nano cap Trevi Therapeutics ( TRVI +56.8% ) is up on double normal volume, a scant 16K shares, on the heels of its Q4 report that included an update on its two lead indications. More news on: Trevi Therapeutics, Inc., Healthcare stocks news, Stocks on the move, ...

Trevi Therapeutics (NASDAQ: TRVI ): Q4 Net loss of $6.54M. More news on: Trevi Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Enrollment in PRISM Study Progressing - Sample Size Re-estimation Planned for mid-2020 Expect to Report Top-Line Data in both PN and IPF-Cough Trials in Second Half of 2020 Cash Position of $57.3 Million Expected to Fund Operations into the Third Quarter of 2021 NEW HAVEN, Conn...

NEW HAVEN, Conn., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that management will...